A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
View abstract on PubMed
Summary
This summary is machine-generated.Obeticholic acid significantly improved liver enzymes in primary biliary cholangitis patients unresponsive to ursodiol. While effective, it increased adverse events compared to placebo.
Area Of Science
- Hepatology
- Gastroenterology
- Clinical Pharmacology
Background
- Primary biliary cholangitis (PBC) can lead to cirrhosis and death, with limited treatment options.
- Alkaline phosphatase and bilirubin levels are key indicators of PBC progression and prognosis.
- Obeticholic acid, a farnesoid X receptor agonist, presents a potential therapeutic avenue for PBC.
Purpose Of The Study
- To evaluate the efficacy and safety of obeticholic acid in patients with primary biliary cholangitis.
- To assess the impact of obeticholic acid on liver biochemistry markers compared to placebo.
Main Methods
- A 12-month, double-blind, placebo-controlled, phase 3 trial involving 217 patients with PBC.
- Patients received either obeticholic acid (5-10 mg or 10 mg) or placebo, often with background ursodiol therapy.
- The primary endpoint was achieving specific alkaline phosphatase and total bilirubin levels.
Main Results
- Obeticholic acid groups showed significantly higher rates of achieving the primary endpoint (46-47%) versus placebo (10%).
- Both obeticholic acid doses led to substantial reductions in alkaline phosphatase and total bilirubin levels (P<0.001).
- Increased incidence of pruritus and serious adverse events was observed in obeticholic acid groups compared to placebo.
Conclusions
- Obeticholic acid demonstrates significant efficacy in improving liver biochemistry in PBC patients.
- The drug offers a beneficial treatment option for those with inadequate response or intolerance to ursodiol.
- Increased adverse events necessitate careful monitoring and risk-benefit assessment in clinical practice.